Objective:

To describe a possible association between betahistine exposure and depressive symptoms with suicidal ideation.

Approach:

• Case Report: A 33-year-old male patient treated for dizziness experienced depressive symptoms and suicidal ideation after betahistine treatment.
• Literature Review: The researchers reviewed prior database-level signals and adverse event reports related to betahistine.

Key Findings:

• The patient developed low mood and suicidal ideation after rechallenging with betahistine.
• Symptoms resolved completely within 2 days of discontinuing betahistine.
• The adverse drug reaction was classified as 'probable' based on established assessment scales.

Interpretation:

The researchers noted the close temporal association between betahistine use and the emergence of depressive symptoms.

Limitations:

• Single-case design limits generalizability.
• Inability to establish definitive causality.
• Potential recall bias and lack of structured psychiatric assessment.

Conclusion:

The authors emphasized vigilance for neuropsychiatric adverse reactions to histamine receptor-active drugs, as symptoms may occur close to treatment initiation.

Sources:

• Medicine